Date: 2013-01-25
Type of information: Fundraising
Company: Cytox (UK)
Investors:
Amount: £3.5 million (€4 million)
Funding type:
Planned used:
Others: Cytox, a developer of the blood biomarker, ADpredict™, using a proprietary cell cycle approach for Alzheimer\'s disease, has announced a £3.5 million (€4 million) injection from new and existing backers. ADpredict™, a blood-based test in development for identifying AD in early symptomatic patients, was developed by Cytox’s Science Director, Dr Zsuzsanna Nagy, Lead of the Neurodegeneration and Repair team based at the University of Birmingham.
Cytox has also unveiled the completion of a study sponsored by Roche on ADpredict™. Cytox says the results further build their confidence that the assay will become an important tool to assist pharma companies in their development of new therapies. The results will be used to refine the next steps in assay validation and clinical development. ADpredict™ has now been tested in close to 300 subjects in three clinical studies; the new data from this has been submitted for publication.
Therapeutic area: Diagnostic
